article thumbnail

Targeting AML with New Generation T-Cell Therapies – Xtalks Life Science Podcast Ep. 162

XTalks

Tune into the episode to learn about CERo’s next-gen T-cell technology and its lead therapeutic candidate, a CER T cell product that contains a phagocyte receptor component. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

article thumbnail

10 Key Learnings from Successful Cellular and Gene Therapy Trials for Rare Diseases

XTalks

Awareness of rare diseases is growing, and with a better understanding of the pathophysiology of many rare diseases, innovative treatment options are emerging, like gene therapies that can treat the root cause of rare genetic diseases and potentially provide long-term symptom relief, or even a definitive cure.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sarepta’s Elevidys Reaches Finish Line as First Gene Therapy Approved for Duchenne Muscular Dystrophy

XTalks

Gene therapies for Duchenne muscular dystrophy (DMD) have been an area of intense research and Sarepta’s Elevidys is now the first one to be approved by the US Food and Drug Administration (FDA). million price tag of Elevidys, a one-time gene therapy. Options for managing the symptoms of DMD have been limited.

article thumbnail

Top Life Science News and Trends in 2023 at Xtalks

XTalks

In 2023, there were significant advancements and notable trends in the life sciences. Xtalks compiled a list of its top life science news and trends of 2023, which provided readers with the latest developments, information and expert insights across life science industries, including pharma, biotech and medical device.

article thumbnail

New blood donor centre opens in Glasgow

Drug Discovery World

A new blood donor centre in Glasgow, Scotland has been opened to support cell and gene therapy research. . BioIVT’s new facility is located in the West of Scotland Science Park, which is home to more than 40 life science and technology businesses. .

article thumbnail

Sensorion and Novasep Announce Signature of a Gene Therapy Product Development and Manufacturing Agreement

The Pharma Data

The agreement covers the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein. Sensorion is currently advancing two preclinical gene therapy programs conducted under a broad multi-program research partnership with the Genetics and Physiology of Hearing Unit at Institut Pasteur (Paris).

article thumbnail

Filsuvez Topical Gel Gets FDA Approval for Epidermolysis Bullosa

XTalks

Filsuvez topical gel is a sterile botanical drug product designed for topical use, containing birch triterpenes within an oil base. For instance, Vyjuvek , the first FDA-approved gene therapy for DEB, is priced at $24,250 per vial. Vyjuvek is a gene therapy that employs a herpes simplex virus type 1 (HSV-1) vector.